Impact of Androgen Deprivation Therapy on Mortality of Prostate Cancer Patients with COVID-19: A Propensity Score-Based Analysis

The document presents a study analyzing the effect of androgen deprivation therapy (ADT) on the mortality rate of 199 prostate cancer patients who contracted COVID-19. The results showed that 78.4% of the patients were actively using ADT, and 63.3% of the total cohort died from COVID-19. However, the active use of ADT was not found to be a protective factor against death from COVID-19. The study concluded that active use of ADT was not associated with a reduced risk of death in prostate cancer patients with COVID-19, even after adjusting for various factors using propensity score-based pair matching and double robust estimation with inverse weight.